Objective: The emergence of novel oral anticoagulant agents (NOACs) has increased the ability of physicians to provide patients with reliable anticoagulation (AC) therapy for venous thromboembolism (VTE). Their effectiveness in comparison to vitamin K antagonists as well as their relative safety profile is well documented in the literature. The treatment of VTE continues to evolve, and data suggest a therapeutic advantage of pharmacomechanical thrombolysis combined with AC over AC alone in the treatment of select patients with VTE. However, the relative lack of knowledge regarding NOACs among physicians coupled with the lack of approved reversal agents limits their widespread use. Vitamin K antagonists remain the mainstay of long-term outpatient oral AC therapy. Even with the present data, the safety of NOACs after advanced therapies with tissue plasminogen activator (tPA) remains unclear. We set out to study the safety of NOACs, specifically Xa inhibitors, immediately after thrombolysis therapy with tPA in patients with VTE.
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Methods: A retrospective review of patients' records at a single institution was conducted. Our study included patients who underwent catheter-directed thrombolysis (CDT) with tPA for VTE, with subsequent early initiation of an NOAC, from January 2015 to September 2017. Data were collected on demographics, characteristics of VTE, treatment modality, and outcomes. All patients had a minimum follow-up of 3 months. End points were bleeding complications as defined by Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) criteria and recurrence of VTE.
Results: A total of 42 patients (52% female; mean age, 55 years) underwent CDT with an EkoSonic catheter (EKOS Corporation, Bothell, Wash) and tPA while AC was maintained with intravenous unfractionated heparin. Completion of CDT was followed by initiation of an NOAC; 80% of patients were treated with CDT for submassive pulmonary embolism (mean tPA dose, 24 mg) and the remainder for extensive deep venous thrombosis (mean tPA dose, 12 mg). All patients were transitioned to an oral direct Xa inhibitor on postprocedure day 1 (74% to apixaban vs 26% to rivaroxaban). No bleeding complications were recorded in any of the patients, independent of tPA dose, type of VTE treated, or therapeutic oral agent used. No VTE recurrences were encountered at 3-month follow-up.
Conclusions: NOACs, specifically direct Xa inhibitors, appear to be a safe therapeutic option for patients with VTE undergoing CDT with tPA. In our study, neither bleeding complications nor recurrent VTEs were observed. Our study is limited by its retrospective nature and small sample size. Larger prospective studies are needed to confirm these results. Objective: Current guidelines for acute venous thromboembolism recommend placement of inferior vena cava (IVC) filters for therapeutic or prophylactic purposes in patients who cannot tolerate or adhere to anticoagulation. There is conflicting evidence about the safety and determinants of filter-related complications. Therefore, the aim of this study was to report the incidence of filter complications in general contemporary practice.
Methods: The Vascular Quality Initiative registry (2013-present) was explored. Immediate insertion filter-related complications were defined as a composite of any of the following: venous injury, placement complications (failed to open properly, deployed >20 mm from intended site, wrong vein, or embolized to the heart), angulation of >20 degrees, and insertion site complications (deep venous thrombosis, hematoma, pseudoaneurysms requiring transfusion or surgery). Late complications were migration, angulation, fracture, thrombosis, fragment embolization, and perforation. Survival analysis was employed to examine late filter-related complications, accounting for patient and operative factors including age, sex, race, hypertension, diabetes mellitus, chronic kidney disease, obesity, thrombotic state, aspirin, statin, P2Y 12 antagonists, oral anticoagulants, imaging technique, renal vein visualization, insertion and landing sites, and abnormal anatomy. Analysis was clustered by centers. Patients were censored if they developed complications, filter retrieval, or death.
Results: A total of 7788 patients were examined. Mean follow-up time was 1.2 years (61.2 years; range, 0-4.8 years). Immediate complications were 2.3% (venous injury, 0.7%; placement complications, 0.5%; angulation, 1.4%; insertion site complications, 0.4%). Late complications occurred in 3.4% (migration, 0.07%; angulation, 0.7%; fracture, 0.07%; caval or iliac vein thrombosis: 0.8%; in-filter thrombus, 1.6%; fragment embolization, 0.02%; perforation, 0.6% Conclusions: This study reports the occurrence of IVC filter-related complications in a multicenter national data set. The immediate device complication rate was 2.3%, whereas late complication rate was 3.4%. Both could be mitigated with use of ultrasound or intravascular ultrasound to guide IVC filter insertion. Patients' characteristics or comorbidities did not seem to have an impact on device complications.
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